NAMI & Eli Lilly partners in bankrupting state Medicaid budgets – NYT Sat, 20 Dec 2003 The New York Times reports that Medicaid expenditure for prescription drugs has escalated to $27.5 billion. These costs are up 19% from last year. Antipsychotic drugs, such as Eli Lilly’s Zyprexa, eat up more…
Dr. Carl Elliott's insightful essay in SLATE:: Why do drug companies want to give money to bioethicists in the first place? In the public relations business, this approach is called "third-party strategy."
Double Dipping at NIH: “the Gaming Must End” – Editorial WashPost Tue, 6 Jul 2004 Monday’s Washington Post editorial took a critical of the corrupting influence of the pharmaceutical industry on scientists at the National Institutes of Health. The agency’s “lax ethics rules, laxly enforced” has resulted in scientists “[pocketing]…
AHRP Correspondence with Government Agencies related link: FDA response to AHRP procedural questions (FDA sham conflicts of interest policy) FDA re: supression of SSRI evidence ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave, Suite 28P New York, NY 10023 https://ahrp.org Tel: 212-595-8974 e-mail: October 29, 2003 To: Thomas…
WSJ: Court Revives Suit Against Pfizer On Nigeria Study Tue, 14 Oct 2003 Follow up to earlier AHRP Infomail on this case. The Wall Street Journal reports: “The suit against Pfizer is part of a growing trend in international law to try cases against multinational corporations in developed countries for…
Walk-in Drug Trial Clinic NYC Upper East Side Wed, 17 Sep 2003 While ethics is currently a hot topic at universities, and ethics committees and conferences have become a growth industry within the research community, ethics has not affected the increasing commercialization of medicine and clinical trials. Dr. Ronald Fieve,…
Comments submitted by The Alliance for Human Research Protection Re: Best Pharmaceuticals for Children’s Act of 2002 The National Academy of Sciences Committee of the Institute of Medicine on Clinical Research Involving Children August 18, 2003 Vera Hassner Sharav, President John H. Noble, Jr., Ph.D, Treasurer David Cohen, Ph.D, Secretary…
AHRP has been closely monitoring pediatric research trends since passage of the FDA Modernization Act of 1997. We believe that medications used in children should be thoroughly tested for safety, effectiveness and appropriate dose. But unlike adults who can exercise their autonomous right to informed consent, children who are enrolled in clinical trials are non-consensual human subjects. They should not, therefore, be made to assume the burden of testing possibly toxic drugs whose safety is unknown.
Debate Resumes on the Safety of Depression’s Wonder Drugs – NYT Thu, 7 Aug 2003 After a decade of lies, deception, and cover-up of evidence linking antidepression drugs – such as, Prozac, Paxil, Zoloft – to acts of suicide in previously non-suicidal people – children and adults, some of who…
Infomail Archive 2003 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 19, 2003: Eli Lilly Prozac UK Fact Sheet: “Not Recommended” for Children – PMDD Withdrawn in UK Dec 19, 2003: Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Dec 18, 2003:…
Rate of Preschool Kids Prescribed Antidepressants Skyrockets – Cong Investigates FDA Fri, 2 Apr 2004 A new survey by Express Scripts found the rate at which American children are prescribed antidepressants almost doubled (49%) in 5 years. The steepest unfathomable, medically unsupportable, increase–64%–was among preschool children. This is evidence of…
Rehnquist Warns Drug Makers _Marketing Actimune for Unapproved Use_NYT Mon, 28 Apr 2003 1. The New York Times reports that Janet Rehnquist, the Inspector General of the Department of Health and Human Services, has issued “a compliance guide for drug manufacturers” in which they are waned that many of their…
